title: Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
abstract: Donor lymphocyte infusion (DLI) can restore remission in a high percentage of patients with chronic myeloid leukaemia (CML) who relapse after allogeneic stem cell transplant (SCT). Subsequent relapses after a DLI-induced remission do occur and the optimal management of these patients is not defined. A retrospective study of the practice of UK transplant centres was conducted. In all, 13 patients from seven centres were identified: all were treated for relapse post allogeneic SCT with DLI and achieved either a complete cytogenetic (n=5) or molecular (n=8) remission. All patients subsequently had a second relapse, at molecular (n=7), cytogenetic (n=4) and haematological (n=2) levels. Further DLI was used in the treatment of 11 patients, imatinib mesylate in three and chemotherapy in two. The two patients with haematological relapse died of blastic disease. The remaining 11 patients achieved either a complete cytogenetic (n=2) or molecular (n=9) remission. Nine patients remain in molecular remission at a median follow-up of 29 months, seven of whom had received DLI alone as treatment for second relapse, one DLI plus imatinib and one imatinib alone. Toxicity following DLI for second relapse was low. Longer follow-up will be required to see if these second DLI-induced remissions will be durable.
authors.affiliation: Adult BMT Unit, Bristol Royal Children's Hospital, Bristol, UK.
authors.forename: M
authors.initials: M
authors.lastname: Cummins
authors.forename: K
authors.initials: K
authors.lastname: Cwynarski
authors.forename: S
authors.initials: S
authors.lastname: Marktel
authors.forename: F
authors.initials: F
authors.lastname: Dazzi
authors.forename: J
authors.initials: J
authors.lastname: Cavenagh
authors.forename: R E
authors.initials: RE
authors.lastname: Clark
authors.forename: T L
authors.initials: TL
authors.lastname: Holyoake
authors.forename: D
authors.initials: D
authors.lastname: Milligan
authors.forename: A
authors.initials: A
authors.lastname: Parker
authors.forename: N H
authors.initials: NH
authors.lastname: Russell
authors.forename: D I
authors.initials: DI
authors.lastname: Marks
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D002986:Clinical Trials as Topic; D004358:Drug Therapy / Q000379:methods; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008214:Lymphocytes / Q000166:cytology* / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012008:Recurrence; D012074:Remission Induction; D012189:Retrospective Studies; D033581:Stem Cell Transplantation / Q000379:methods; D013997:Time Factors; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D006113:United Kingdom
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate